Stereotactic body radiation therapy for liver oligo-recurrence and oligo-progression from various tumors.
- Author:
Yu Jin CHA
1
;
Mi Sook KIM
;
Won Il JANG
;
Young Seok SEO
;
Chul Koo CHO
;
Hyung Jun YOO
;
Eun Kyung PAIK
Author Information
- Publication Type:Original Article
- Keywords: Liver metastases; Oligo-recurrence; Oligo-progression; Stereotactic radiation therapy
- MeSH: Colon; Disease-Free Survival; Fatigue; Follow-Up Studies; Humans; Liver*; Nausea; Neoplasm Metastasis; Stomach; Survival Rate; Tumor Burden; Vomiting
- From:Radiation Oncology Journal 2017;35(2):172-179
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: To evaluate the outcomes of stereotactic body radiation therapy (SBRT) for patients with liver oligo-recurrence and oligo-progression from various primary tumors. MATERIALS AND METHODS: Between 2002 and 2013, 72 patients with liver oligo-recurrence (oligo-metastasis with a controlled primary tumor) and oligo-progression (contradictory progression of a few sites of disease despite an overall tumor burden response to therapy) underwent SBRT. Of these, 9 and 8 patients with uncontrollable distant metastases and patients immediate loss to follow-up, respectively, were excluded. The total planning target volume was used to select the SBRT dose (median, 48 Gy; range, 30 to 60 Gy, 3–4 fractions). Toxicity was evaluated using the Common Toxicity Criteria for Adverse Events v4.0. RESULTS: We evaluated 55 patients (77 lesions) treated with SBRT for liver metastases. All patients had controlled primary lesions, and 28 patients had stable lesions at another site (oligo-progression). The most common primary site was the colon (36 patients), followed by the stomach (6 patients) and other sites (13 patients). The 2-year local control and progression-free survival rates were 68% and 22%, respectively. The 2- and 5-year overall survival rates were 56% and 20%, respectively. The most common adverse events were grade 1–2 fatigue, nausea, and vomiting; no grade ≥3 toxicities were observed. Univariate analysis revealed that oligo-progression associated with poor survival. CONCLUSION: SBRT for liver oligo-recurrence and oligo-progression appears safe, with similar local control rates. For liver oligo-progression, criteria are needed to select patients in whom improved overall survival can be expected through SBRT.
